Skip to content

Efficacy of Telenutrition for the Treatment of Overweight Patients With Obesity and/or High Cardiometabolic Risk

Efficacy of Telenutrition (OBE-COACH) for the Treatment of Overweight Patients With Obesity and/or High Cardiometabolic Risk

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04941651
Acronym
TOOLBAR
Enrollment
346
Registered
2021-06-28
Start date
2024-01-02
Completion date
2026-11-15
Last updated
2024-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Keywords

Overweight patients, Obesity, Cardiometabolic risk, telenutrition, online nutritional coaching service

Brief summary

The OBE-COACH program is an automated online nutritional coaching service that was evaluated in its first version (MXS-CARE program) in a clinical trial coordinated by our team, in type 2 diabetic patients with abdominal obesity. Results have confirmed the efficiency of the program to improve lifestyle habits, including the 4-month diet, and to reduce weight and HbA1c levels. Based on our experience and the scientific literature, the investigators assume that adherence to the program may diminish in the long term to the point of calling into question its efficiency. So IRIADE compagny developed an enhanced program called OBE-COACH. The OBE-COACH program has been specifically designed to facilitate long-term user adherence. The OBE-COACH program, integrates a bidirectional interactive link between the patient and an automated support system (IRIADE-MED system) associated with an inexpensive remote human support. In the TOOLBAR study, the investigators will evaluate the efficiency of the OBE-COACH solution in a population of obese patients or overweight persons with at least one cardiometabolic risk factor. A group of patients will have access to the OBE-COACH program. It will be compared to a control group which will receive an e-learning program with free access to advice sheets via the web, to a menu generator, videos and a catalog of physical activity, (resources made available by the web site www.mangerbouger.fr (public health France, ministry in charge of health) . Indeed, the investigators judged that the loss of patients during follow-up would be greater if e-learning was not offered in the control group.

Detailed description

The management of patients in the TOOLBAR study will be in accordance with French recommendations: a patient who is overweight should benefit from a dietary, physical activity, psychological assistance and medical monitoring advices which can be provided by a general practitioner. In the control group, subjects have access to an e-learning program, including free access via the web to a nutritional information portal and to automated tools providing information and advice for adopting a balanced, low-carb diet and to practice physical activity in line with the guidelines of the national health nutrition plan (PNNS). However, this group will not have access to the OBE-COACH program. The usual follow-up with the attending doctor will be continued. Patients will be assessed at baseline, 6 months and 12 months. In an ancillary study they could be also assessed at 24 months.

Interventions

BEHAVIORALOBE-COACH program

OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program. The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses. To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals. The intensity level of the program is selected by the user at any time.

DEVICEConnected devices

Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program. The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate. The balance (Web coach premium, Terraillon) is a connected scale to collect body weight.

DEVICEConnected Activity Tracer

The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.

e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Men or women 18 to 75 years * Obesity defined by a body mass index \> 30 kg / m2 or a BMI\> 25 kg / m2 with the presence of at least one major cardiometabolic risk factors among the followings: dyslipidemia, hypertension, diabetes, prediabetes * Stable weight in the last six months (weight variation \< 4 kg peak-to-peak) * Access and current use of internet, possession of an email address and a smartphone. * Understanding and reading French * Patient not currently following a nutritional monitoring and not having planned to be engaged in a nutritional monitoring during the coming year

Exclusion criteria

* Excessive alcohol consumption \> 30 g / day -Pregnant or breastfeeding woman * symptomatic cardiovascular disease : angina, lower extremity arterial occlusive disease, stroke or myocardial infarction dating of less than 6 months. * Uncontrolled psychiatric illness * Patients receiving or about to receive during the study period a systemic or local treatment susceptible to interfere with the evaluation of the primary criteria (corticosteroids, antipsychotics, tricyclic antidepressants) except if these treatments have been stable for at least 6 months without a plan to modify the dose during the 12 months of the study * Adhering to a prescribed diet for weight loss, in the past 3 months * Person with a severe eating disorder: bulimia, binge eating disorder according to DSM-V criteria - Presence of celiac disease, Crohn's disease or other metabolic disorder or condition affecting nutritional needs such as allergies or food intolerances (except partial lactose intolerance) * Anticipated difficulties in following the patient * Lack of social coverage in France * Lack of written or electronic informed consent

Design outcomes

Primary

MeasureTime frameDescription
Weight reduction of at least 5% between 0 and 12 months.12 monthsWeight reduction of at least 5% between 0 and 12 months. The weight, in Kg, will be measured in a state of fastness ≥ 8h, in participants wearing light clothing without shoes on the same scales calibrated at inclusion and 12 months of follow-up.

Secondary

MeasureTime frameDescription
Triglycerids change between 0 and 12 months12 monthsPlasma fasting levels of triglycerides in g/L
HDL cholesterol change between 0 and 12 months12 monthsPlasma fasting levels of HDL cholesterol in g/L
Weight reduction of at least 5% between 0 and 6 months.6 monthsWeight, in Kg, measured in the same conditon at baseline and 6 months.
Weight change between 0 and 6 months6 monthsWeight, in Kg, measured in the same conditon at baseline and 6 months.
Weight change between 0 and 12 months12 monthsWeight, in Kg, measured in the same conditon at baseline and 12 months.
Waist change between 0 and 6 months6 monthsWaist, in cm, measured midway between the last ribs and the anterior superior iliac crest
Waist change between 0 and 12 months12 monthsWaist, in cm, measured midway between the last ribs and the anterior superior iliac crest
non-HDL cholesterol change between 0 and 12 months12 monthsPlasma fasting levels of non-HDL cholesterol in g/L (total cholesterol less HDL-C)
Blood glucose change between 0 and 12 months12 monthsPlasma fasting levels of glucose in g/L
HbA1c change between 0 and 12 months12 monthsPlasma fasting levels of HbA1c in percentage
Systolic blood pressure change between 0 and 12 months12 monthsSystolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Diastolic blood pressure change between 0 and 12 months12 monthsDiastolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Triglycerids change between 0 and 6 months6 monthsPlasma fasting levels of triglycerides in g/L
HDL cholesterol change between 0 and 6 months6 monthsPlasma fasting levels of HDL cholesterol in g/L
LDL cholesterol change between 0 and 6 months6 monthsPlasma fasting levels of LDL cholesterol in g/L
non-HDL cholesterol change between 0 and 6 months6 monthsPlasma fasting levels of non-HDL cholesterol in g/L (total cholesterol less HDL-C)
Blood glucose change between 0 and 6 months6 monthsPlasma fasting levels of glucose in g/L
HbA1c change between 0 and 6 months6 monthsPlasma fasting levels of HbA1c in percentage
Systolic blood pressure change between 0 and 6 months6 monthsSystolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Diastolic blood pressure change between 0 and 6 months6 monthsDiastolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Change in adherence to the Mediterranean diet : Score PREDIMED12 monthsChange between 0 and 12 months of adherence to mediterranean diet,evaluated by the dietetic score PREDIMED (validated checklist of 14 items). Higher scores indicate greater adherence to the diet assigned
Change in adherence to the Mediterranean diet : fruits and vegetables consumption12 monthsChange between 0 and 12 months in terms of perrcentage of consumption of fruits and vegetables on the recommended 400 g/day
Change between 0 and 12 months of Energy intake12 monthsEnergy intake, in Kcal/day, evaluated with the validated NAQA questionnaire
Change between 0 and 12 months of proteins intake, in g/day, evaluated with the validated NAQA questionnaire12 months
Change between 0 and 12 months of sucrose intake in g/day, evaluated with the validated NAQA questionnaire12 months
Change between 0 and 12 months of lipids intake in g/day, evaluated with the validated NAQA questionnaire12 months
Change between 0 and 12 months of cholesterol intake12 monthsCholesterol intake, in mg/day, evaluated with the validated NAQA questionnaire
Change between 0 and 12 months of calcium intake in mg/day, evaluated with the validated NAQA questionnaire12 months
Change between 0 and 12 months of sugary drinks consumption in number of glasses/day12 months
Change between 0 and 12 months of alcohol drinks consumption in number of glasses/day12 months
Change between 0 and 6 months of sugary drinks consumption in number of glasses/day6 months
Change between 0 and 6 months of alcohol drinks consumption in number of glasses/day6 months
Change between 0 and 12 months of tobacco consumption in number of cigarettes/day12 months
Change between 0 and 6 months of tobacco consumption in number of cigarettes/day6 months
Change between 0 and 12 months of Adherence to the WHO recommendations for physical activity, measured in Metabolic Equivalent of Task, MET, evaluated with the GPAQ questionnaire.12 months
Change between 0 and 6 months of Adherence to the WHO recommendations for physical activity, measured in Metabolic Equivalent of Task, MET, evaluated with the GPAQ questionnaire.6 months
Adherence to OBE-COACH program at 12 months, evaluated by the average percentage of questions (sent by IRIADE) with replies from the subject per week during the previous month.12 months
Adherence to OBE-COACH program at 12 months, evaluated by the number of participation in web focus groups over the last 6 months.12 months
LDL cholesterol change between 0 and 12 months12 monthsPlasma fasting levels of LDL cholesterol in g/L
Adherence to OBE-COACH program at 6 months, evaluated by the number of participation in web focus groups over the last 6 months.6 months
Change between 0 and 12 months of Food impulsivity evaluated by the TFEQ21 questionnaire12 months
Change between 0 and 6 months of Food impulsivity evaluated by the TFEQ21 questionnaire6 months
Evolution between 0 and 12 months of Symptoms of anxiety, measured with the HAD questionnaire (score 0 to 21)12 months
Adherence to OBE-COACH program at 6 months, evaluated by the average percentage of questions (sent by IRIADE) with replies from the subject per week during the previous month.6 months

Countries

France

Contacts

Primary ContactMarylou Para, PHU
marylou.para@aphp.fr01 40 25 84 50
Backup ContactBoris Hansel, MD, PhD
boris.hansel@aphp.fr01 40 25 87 35

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026